Novel antiangiogenic therapies for renal cell cancer.

Published

Journal Article (Review)

Renal cell cancer remains a disease for which highly effective therapy for the majority of patients with metastatic disease is lacking. The biology of clear cell carcinomas and their association with mutations of the von Hippel-Lindau gene and its resultant increased expression of vascular endothelial growth factor (VEGF) make angiogenesis a potentially pathophysiologic mechanism for tumor development. As a result, the use of antiangiogenic therapy is an intriguing concept for the treatment of renal cell cancer. Various agents, aside from the inhibitors of VEGF, have been studied, including thalidomide, low-dose interferon, and novel antiangiogenic agents such as the thrombospondin-1 mimetics. Use of these agents has been associated with some degree of objective response or prolonged stabilization of disease, and their true value needs to be assessed in ongoing prospective studies. Combinations of antiangiogenic agents either with other similarly acting drugs or as a component of a "cocktail" with other noncytotoxic therapies should be explored in this patient population.

Full Text

Duke Authors

Cited Authors

  • Gordon, MS

Published Date

  • September 15, 2004

Published In

Volume / Issue

  • 10 / 18 Pt 2

Start / End Page

  • 6377S - 6381S

PubMed ID

  • 15448034

Pubmed Central ID

  • 15448034

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-050007

Language

  • eng

Conference Location

  • United States